AMAG PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF VYLEESI™ (BREMELANOTIDE INJECTION) FOR ACQUIRED, GENERALIZED HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) IN PREMENOPAUSAL WOMEN – AMAG Pharmaceuticals
AMAG PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF VYLEESI™ (BREMELANOTIDE INJECTION) FOR ACQUIRED, GENERALIZED HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) IN PREMENOPAUSAL WOMEN – AMAG Pharmaceuticals — Leer en http://www.amagpharma.com/news/amag-pharmaceuticals-announces-fda-approval-of-vyleesi-bremelanotide-injection-for-acquired-generalized-hypoactive-sexual-desire-disorder-hsdd-in-premenopausal-women/ Nuevo fármaco aprobado para el deseo sexual hipoactivo, por la FDA. Próxima comercialización, su mecanismo de acción no está bien establecido, pero parece […]
